Patents Examined by Marsha Tsay
  • Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers
    Patent number: 11203747
    Abstract: The present invention relates to methods for purifying or enriching a biomolecule using multimodal resins and an elution buffer containing a Good's buffer.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: December 21, 2021
    Assignee: Genzyme Corporation
    Inventors: Rahul Godawat, Daniel Cummings, Veena Warikoo
  • Recombinant VWF formulations
    Patent number: 11191837
    Abstract: The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: December 7, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Peter Matthiessen, Peter Turecek, Hans-Peter Schwarz, Kurt Schnecker
  • Allelic variants of human factor VIII
    Patent number: 11185573
    Abstract: Disclosed are compositions and methods related to Factor VIII.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: November 30, 2021
    Assignee: Haplomics, Inc.
    Inventor: Thomas E. Howard
  • Chimeric clotting factors
    Patent number: 11168316
    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 9, 2021
    Assignee: Bioverativ Therapeutics, Inc.
    Inventors: Joe Salas, Elena Kistanova, Vu Phong Hong, Adam R. Mezo, Robert T. Peters
  • Implantable biosensor and methods of use thereof
    Patent number: 11160474
    Abstract: Provided herein is a stabilized oxygen transport matrix that includes a reversible oxygen binding protein, such as hemoglobin, immobilized throughout the stabilized oxygen transport matrix. The stabilized oxygen transport matrix is used to transport oxygen and can be used as an oxygen transport region and a reaction region of an analyte sensor, such as an implantable glucose sensor. The reversible binding protein can also function as an oxygen probe within the analyte sensor.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 2, 2021
    Assignee: Metronom Health, Inc.
    Inventors: Elliot Botvinick, Troy M. Bremer
  • Asx-specific protein ligase
    Patent number: 11124788
    Abstract: The present invention is directed to enzymes having Asx-specific ligase and cyclase activity and to nucleic acids encoding those as well as methods of the manufacture of said enzymes. Further encompassed are methods and uses of these enzymes.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: September 21, 2021
    Assignee: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Kien Truc Giang Nguyen, James P. Tam
  • Euglobulin-based method for determining the biological activity of defibrotide
    Patent number: 11085043
    Abstract: It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 10, 2021
    Assignee: GENTIUM S.R.L.
    Inventors: Terenzio Ignoni, Vijay Kumar, Khalid Islam
  • Chimera protein comprising FVIII and vWF factors, and use thereof
    Patent number: 11046749
    Abstract: A chimera protein according to the present application has a significantly increased in vivo half-life when administered because of a vWF domain coupled to FVIII, such that when used as a hemophilia A therapeutic agent, convenience for patients can be increased and medical expenses can be reduced.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 29, 2021
    Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Injae Oh, Seung-Hoon Lee, Eui-Cheol Jo, Mee Sook Oh, Jae Hwan Ryu, Yong Jae Kim, So Ra Kim, Jin-hyun Park
  • Device and method for preparing and administering one-component fibrin sealant
    Patent number: 11020100
    Abstract: Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: June 1, 2021
    Assignees: Omrix Biopharmaceuticals, Ltd., Ethicon, Inc.
    Inventors: Ashley DeAnglis, Yair Pilpel, Yuri Zherdev, Sivan Doron, Lior Erez
  • Factor VIII formulations
    Patent number: 11020459
    Abstract: A Factor VIII (FVIII) composition formulated such that NaCl is not present in the final formulation or is present in trace amounts, which allows for a concomitant reduction in the lyophilization cycle time and increased stability of the lyophilized FVIII.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: June 1, 2021
    Assignees: Baxalta Incorporated, Baxalta GmbH, University of Connecticut
    Inventors: Michael Pikal, Serguei Tchessalov, Erik Bjornson, Feroz Jameel, Marc Besman
  • Sand worm lyophilisate and uses thereof
    Patent number: 10988730
    Abstract: The invention relates to a lyophilisate or to a powder including i) at least one globin, a globin protomer or an extracellular hemoglobin from annelids, and ii) at least one biological material from annelids that is different from said globin, from said protomer and from said hemoglobin.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 27, 2021
    Assignee: Hemarina
    Inventor: Franck Zal
  • Methods and compositions for regulation of transgene expression
    Patent number: 10975375
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: April 13, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Methods and compositions for preparing surfactant protein D (SP-D)
    Patent number: 10975389
    Abstract: Some embodiments of the methods and compositions provided herein relate to the preparation surfactant protein-D (SP-D). Some embodiments include the expression of human SP-D in certain cell lines, and the purification of human SP-D from such cell lines. Some embodiments include the preparation of certain oligomeric forms of human SP-D.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: April 13, 2021
    Assignee: Airway Therapeutics, Inc.
    Inventors: Jan Susan Rosenbaum, Frederick Gyapon Quast, Matthias Kaup, Lars Stöckl
  • Purification of chimeric FVIII molecules
    Patent number: 10947269
    Abstract: The invention is directed to methods of purifying a chimeric protein comprising subjecting the chimeric protein to a factor VIII-specific affinity chromatography, and subjecting the chimeric protein to an AEX chromatography; wherein the chimeric protein comprises a factor VIII protein or a fragment thereof. The chimeric protein purified by the present methods shows improved factor VIII activity.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 16, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Lily Zhu, Anxhela Kole, John Kulman, Marisol Acosta
  • Silk fibroin-based microneedles and methods of making the same
    Patent number: 10933173
    Abstract: A microneedle or microneedle device includes a microneedle body extending from a base to a penetrating tip formed from a silk fibroin based material, which is easy to fabricate and highly biocompatible. The microneedle device can include one or more microneedles mounted to a substrate. The silk fibroin can include active agents to be transported into or across biological barriers such as skin, tissue and cell membranes. The silk fibroin microneedles can be fully or partially biodegradable and/or bioerodible. The silk fibroin is highly stable, affords room temperature storage and is implantable. The silk fibroin structure can be modulated to control the rate of active agent delivery.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: March 2, 2021
    Assignee: Trustees of Tufts College
    Inventors: David L. Kaplan, Konstantinos Tsioris, Fiorenzo G. Omenetto, Eleanor M. Pritchard
  • Fluorescent protein
    Patent number: 10899804
    Abstract: Provided is a green-yellow fluorescent protein with high pH stability (with reduced pH sensitivity). In one or more embodiments, the fluorescent protein is a fluorescent protein comprising an amino acid sequence from position 2 to 225 of the amino acid sequence of SEQ ID NO: 1, at least a mutation being introduced into the sequence, wherein the above-mentioned mutation is selected from the group consisting of F149T or S or A, L158T or S or A, H160T or S or A, Y174T or S or A, and Y192T or S or A as well as combinations of 2 to 5 thereof.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: January 26, 2021
    Assignee: Osaka University
    Inventors: Takeharu Nagai, Hajime Shinoda, Tomoki Matsuda, Yuanqing Ma
  • Compounds and methods for the production of suckerin and uses thereof
    Patent number: 10899803
    Abstract: Sucker ring tooth (SRT) proteins called Suckerins were identified from the sucker tissue of three distantly related Decapodiformes species. These proteins assemble into silk-like beta-sheet reinforced materials. The use of suckerin proteins to produce fibres, films and tissue scaffolds is also described.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: January 26, 2021
    Assignees: Nanyang Technological University, Agency for Science, Technology and Researech
    Inventors: Paul Andre Guerette, Ali Gilles Tchenguise Miserez, Shawn Hoon
  • Enzyme variants with improved ester synthase properties
    Patent number: 10894953
    Abstract: The disclosure relates to enzyme variants with improved ester synthase properties for the production of fatty acid esters. Further contemplated are recombinant host cells that express such variants, cell cultures comprising the recombinant host cells and fatty acid ester compositions produced by such recombinant host cells.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 19, 2021
    Assignee: Genomatica, Inc.
    Inventors: Andrew M. Shumaker, Bernardo M. da Costa, Kevin Holden, Louis G. Hom, Tarah S. Baron, Noah Helman
  • Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
    Patent number: 10883097
    Abstract: The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: January 5, 2021
    Assignee: DRK-BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBH
    Inventors: Erhard Seifried, Jörg Schüttrumpf
  • Mutant lysenin pores
    Patent number: 10882889
    Abstract: The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using lysenin.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 5, 2021
    Assignee: Oxford Nanopore Technologies Ltd.
    Inventors: Mark Bruce, James Anthony Clarke, Andrew John Heron, Lakmal Jayasinghe, Elizabeth Jayne Wallace